All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody linked to 4-1BB (CD137) and CD3ζ signaling domains. And the vector product was designed for the treatment of glioblastoma.
CAR Construction : 3C10 scFv-BBζ Fig.1 Flow cytometry analysis of SMAD2/3 phosphorylation induced by TGFβ in anti-EGFRvIII CAR or TGFβ-trapped anti-EGFRvIII CAR T cells. Functional characterization of TGFβ-trapped EGFRvIII-specific CAR T cells. Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117. |
CAR Construction : 3C10 scFv-BBζ Fig.2 Cytotoxicity of mock CAR-Ts, anti-EGFRvIII (3C10) CAR-Ts, TGFβ-trapped anti-EGFRvIII CAR (3C10CAR-TGFRII) T cells against EGFRvIII+ target cells in the presence or absence of TGFβ. Functional characterization of TGFβ-trapped EGFRvIII-specific CAR T cells. Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117. |
CAR Construction : 3C10 scFv-BBζ Fig.3 TGFβ-trapped anti-EGFRvIIII CAR-T more effectively controls tumor growth in orthotopic GBM models. Kaplan-Meier survival curves of U87-EGFRvIII-luc-bearing mice treated with different CAR-Ts. Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117. |
CAR Construction : 3C10 scFv-BBζ Fig.4 TGFβ-trapped CAR-T treatment increased CAR-Ts infiltration and convert infiltrated-microglia to pro-inflammatory phenotype. Representative dot plots showing the proportion of infiltrated hCD3+ CAR-T cells in cells suspension (left); quantification of CD3+T cell infiltration in different treatment groups (right). Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117. |
CAR Construction : 3C10 scFv-BBζ Fig.5 Immunohistochemistry of IbaI+ microglia in glioma tissue showing the number of infiltrated microglia increased in 3C10CAR-TGFRII group and morphology change (red arrow). In contrast to the ramified appearance of that in the mock CAR group, infiltrated microglia in the 3C10CAR-TGFRII group had morphology change and showed soma enlargement and process retraction. Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGFRvIII (3C10) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC055). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION